Perindopril and prevention of atrial fibrillation

European Heart Journal, Supplement

Volumn 9, Issue E, 2007, Pages

  Tardif, Jean Claude ^a   Talajic, Mario ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

ACE inhibition; Atrial fibrillation; Hypertension; Perindopril

Indexed keywords

EID: 56349123857     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sum035     Document Type: Article

References (22)

1. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002;287:1003-1010.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002; 360:1903-1913.
3. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;306:1018-1022.
4. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence age distribution gender of patients with atrial fibrillation: analysis implications. Arch Intern Med 1995;155:469-473.
5. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study). Am J Cardiol 1994;74:236-241.
6. Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992; 326:1264-1271.
7. No authors listed. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
8. Morris JJ Jr, Entman M, North WC, Kong Y, McIntosh H. The changes in cardiac output with reversion of atrial fibrillation to sinus rhythm. Circulation 1965;31:670-678.
9. Shapiro W, Klein G. Alterations in cardiac function immediately following electrical conversion of atrial fibrillation to normal sinus rhythm. Circulation 1968;38:1074-1084.
10. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988;9:777-781.
11. Gosselink ATM, Crijns HJGM, van den Berg MP. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994;72:161-166.
12. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347: 1825-1833.
13. Shi Y, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456-461.
14. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104:2608-2614.
15. Madrid AH, Bueno MG, Rebollo JMG, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of ibesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective randomized study. Circulation 2002;106:331-336.
16. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a perspective and controlled study. Eur Heart J 2003; 24:2090-2098.
17. Vermes E, Tardif JC, Bourassa MG, Racine N, Lévesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the studies of left ventricular dysfunction (SOLVD). Circulation 2003;107:2926-2931.
18. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Conolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Coll Cardiol 2005;45:1832-1839.
19. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Antiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004;44:159-164.
20. Roy D, Kerr CR. 2004 Canadian Cardiovascular Society. Canadian Cardiovascular Society Consensus Conference: Atrial Fibrillation 2004. Can J Cardiol 2005;21(Suppl B):9B-10B.
21. Hemmelgarn BR, McAlister FA, Grover S, Myers MG, McKay DW, Bolli P, Abbot C, Schiffrin EL, Honos G, Burgess E, Mann K, Wilson T, Penner B, Tremblay G, Milot A, Chockalingam A, Touyz RM, Tobe SW, the Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part I-Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2006;22:573-581.
22. Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, Leiter LA, Lewanczuk RZ, Schiffrin EL, Hill MD, Arnold M, Moe G, Campbell TS, Hebert C, Milot A, Stone JA, Burgess E, Hemmelgarn BR, Jones C, Larochelle P, Ogilvie RI, Houlden R, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, de Champlain J, Pylypchuck G, Logan AG, Gledhill N, Petrella R, Tobe SW, Touyz RM, the Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II-Therapy. Can J Cardiol 2006;22:583-593.